Skip to main content

Table 2 MR-identified genes/proteins with MG risk

From: Integrative multi-omics analysis identifies genetically supported druggable targets and immune cell specificity for myasthenia gravis

Study/Dataset

Genes/Proteins

Method

SNP

Beta

SE

P value

FDR

OR (95%CI)

P het

Colocalization

eQTLGen

CDC42BPB

IVW

rs10143668

rs11627044

rs12435483

rs192018318

rs2403110

rs75817380

rs77630549

rs8015723

0.527

0.112

2.35 × 10–6

0.006

1.694 (1.361–2.108)

0.648

0.926

eQTLGen

TNFSF12

IVW

rs10468481

rs11078677

rs12449427

rs1641548

rs2292067

rs60370790

rs62059711

rs72842805

rs78378222

0.36

0.085

2.12 × 10–5

0.026

1.433 (1.214–1.691)

0.468

0.305

eQTLGen

CD226

IVW

rs17082031

rs1790974

rs3744856

− 0.428

0.107

6.21 × 10–5

0.039

0.652 (0.528–0.804)

0.649

0.815

eQTLGen

PRSS36

Wald ratio

rs78924645

1.159

0.29

6.40 × 10–5

0.039

3.186 (1.805–5.624)

NA

0.856

ARIC study

PRSS8

Wald ratio

rs1060506

1.447

0.319

5.69 × 10–6

0.004

4.252 (2.275–7.945)

NA

0.982

ARIC study

CPN2

Wald ratio

rs11711157

− 0.2

0.053

1.44 × 10–4

0.034

0.819 (0.739–0.908)

NA

0.926

ARIC study

CTSH

Wald ratio

rs2289702

0.197

0.052

1.44 × 10–4

0.034

1.218 (1.101–1.348)

NA

0.894

INTEVAL study

CTSH

Wald ratio

rs34593439

0.229

0.057

5.49 × 10–5

0.014

1.257 (1.125–1.405)

NA

0.894

  1. The outcome is MG GWAS from Chia et al. (1,873 patients and 36,370 controls); IVW inverse-variance weighted, SE standard error, FDR FDR corrected P value, P het refers to the heterogeneity calculated using the Cochrane Q method; Colocalization indicates PPH4 between eQTLs/pQTLs and MG GWAS